Background: Cyclosporine (CsA) is one of the immunosuppressive drugs, whose pharmacokinetic characteristics vary greatly among individuals. The published data reveal conflicting effects of the polymorphism of MDR1 exon 12 SNP C1236T on the pharmacokinetics of cyclosporine.
Introduction
Cyclosporine is a calcineurin inhibitor used to prevent allograft rejection after transplantation, including solid organ transplantation and stem cell transplantation. Since it is characterized by a narrow therapeutic index and drug interactions occur frequently, its pharmacokinetic characteristics vary greatly among individuals, and daily doses must be adjusted to the whole-blood cyclosporine concentration. [1] It is well clinically recognized that cyclosporine response shows significant interindividual variation among transplant patient. [2] Exposure to cyclosporine is known to be closely associated with the acute rejection rate. Clase et al suggested that early adequate exposure to immunosuppressive agents is critical and that failing to reach target concentrations as early as the third postoperative day may result in acute rejection. [3] Researching on the interindividual variability of cyclosporine pharmacokinetics is of critical importance for adjusting dosage to avoid rejection.
Cyclosporine is a substrate of P-glycoprotein (P-gp) and the product of the multidrug resistance gene (MDR1, also known as ABCB1).
[4] P-gp is a transmembrane efflux pump involving energy-dependent export of xenobiotics from inside to outside the plasma membrane. [5] It may affect the absorption, distribution, and excretion of drugs in the body. MDR1 encodes P-gp and its gene is highly polymorphic. So far, at least 32 single nucleotide polymorphisms (SNP) have been identified. [6] Two synonymous SNPs (C1236T in exon 12 and C3435T in exon 26) and a nonsynonymous SNP (G2677T in exon 21) have been found. [2] Since the initial observation by Anglicheau et al indicated the effect of MDR1 SNP C1236T expression, many studies have been performed on the influence of SNP C1236T on drug metabolism. However, the results were controversial. Haufroid et al [4] Editor: Giovanni Tarantino.
reported no association was found between blood concentrations or dose and MDR1 genotype. Qiu et al demonstrated it had a correlation between MDR1 C1236T and cyclosporine pharmacokinetics in the early stage after transplantation. [7] Fredericks et al suggested MDR1 C1236T did not appear to have a major influence on cyclosporin pharmacokinetics. [8] Moreover, there is no evidence from systematically evaluating the effect of MDR1 C1236T on cyclosporine pharmacokinetics. It remains unclear about the reason for these conflicting results. The limited sample size of each single study could be another reason. Hence, this study conducts a meta-analysis to investigate whether SNP C1236T influences the pharmacokinetics of cyclosporine in transplant patients.
Materials and methods

Literature search
We designed a search strategy via 3 English language databases including PubMed, Embase and Cochrane Library. Four Chinese electronic database including China National Knowledge Infrastructure (CNKI), Wan Fang Database (Wan Fang), Chinese Biomedical Literature Database (CBM), and VIP Database for Chinese Technical Periodicals (VIP) were also searched in Chinese.
The following principal search terms and MeSH headings were used: "cyclosporine" or "ciclosporin" or "CsA" and "polymorphism" or "genotype" or "genes" or "alleles" or "SNP" and "MDR1" or "MDR-1" or "ABCB1." We would look for additional studies in reference lists of included articles, contact with authors about details of published or unpublished articles. The results were crosschecked to eliminate duplicates. The deadline of all retrieval was December 2016.
Study selection
The following studies were included in analysis: patients treated with cyclosporine, regardless of race, sex; patients needed to accept MDR1 Cl236T gene polymorphism detection and detection methods are not limited; and studies published in either English or Chinese. Studies with incomplete information were excluded from the analysis.
Data extraction
Data extraction form designed according to Cochrane Systematic Review Handbook (version 5.3) was used to extract the relevant information independently. Two independent reviewers screened all the titles and abstracts to determine potential usefulness and eligibility of the articles. Then they independently and blindly applied the eligibility criteria to perform the final selection. When discrepancies occurred between both reviewers regarding the inclusion of the articles, they would discuss and identify the reasons of inclusion or exclusion to make an agreement and take a final decision. If they could not reach agreement, a final decision would be based on a third reviewer.
Statistical analysis
Meta-analysis was conducted with RevMan 5.3. The data was pooled and as analyzed for relative risks (RR) with 95% confidence interval (CI). Assessment of heterogeneity was done by I-squared (I 2 ) statistics. A fixed-effects model was initially conducted. If significant heterogeneity was found among trials (I 2 > 50%), a random-effects model was used.
Ethical statement
As all analyses were grounded on previous publications, ethical approval was not necessary.
Results
Study selection and characteristics
A total of 608 records were identified for initial screening and 11 eligible articles were included in this meta-analysis (Fig. 1) . These studies were published between 2004 and 2013. Of these 11 articles, patients from 7 articles were treated with renal transplantation, 3 were treated with bone marrow transplant, and 1 was treated with myasthenia gravis. The meta-analysis results were presented in Table 1 .
Effect of C1236T on dose adjusted C 0
A total of 8 studies in Table 1 .82], P = .1) with no significant heterogeneity (Fig. 2) .
Effect of C1236T on dose adjusted C 2
A total of 3 studies in Table 1 (Fig. 3) .
Effect of C1236T on dose adjusted C max
A total of 3 studies in Table 1 (Fig. 4) .
Effect of C1236T on daily dose
A total of 6 studies in Table 1 (Fig. 5 ).
Effect of C1236T on C 0
A total of 6 studies in Table 1 .00], P = .75). At the same time, the 3 subgroups had no heterogeneity (Fig. 6 ).
Discussion
The characterization of MDR1 gene and the utilization of pharmacogenetic testing for the identification of different MDR1 alleles may provide a useful tool for optimizing therapy involved with drugs that are substrates of P-glycoprotein, which would improve efficacy of drugs and prevent adverse effects. [17] Since the studies on the correlation between genotype of MDR1 C1236T and pharmacokinetics of cyclosporine revealed conflicting results, this meta-analysis mainly assessed the effect of SNP C1236T on pharmacokinetic parameters of cyclosporine.
Pharmacokinetic studies on transplant patients have demonstrated that the area under the concentration time curve (AUC) is a precise predictor of clinical outcomes. [18] However, the AUC methodology is difficult to apply in routine clinical practice, so other methods have been developed to replace the AUC, such as [4] 2004 Renal transplant recipients 50.6 ± 11.2 NR 29/21 Multiple oral dose of CsA adjusted according to blood concentration CC (19) CT (21) TT (10) Qiu et al [9] 2008 Renal transplant recipients 37 ± 9 5 7 ± 7 63/26 Multiple oral dose of CsA adjusted according to blood concentration CC (15) 41 ± 10 57 ± 10 CT (31) 41 ± 10 60 ± 12 TT (43) Ranjana et al [10] 2008 Renal transplant recipients 35.3 ± 10.4 52.9 ± 8.8 131/24 Multiple oral dose of CsA adjusted according to blood concentration (initial 8 mg/kg twice daily)
CC (17) CT (68) TT (70) Fang et al [11] 2008 Renal transplant recipients 44.4 ± 11.9 56.7 ± 9.6 40/25 Multiple oral dose of CsA adjusted according to blood concentration CC (25) CT (35) TT (5) Wang et al [12] 2009 Renal transplant recipients 46.9 ± 13.2 52.3 ± 12.5 59/53 Multiple oral dose of CsA adjusted according to blood concentration CC (18) CT (47) TT (47) Xin et al [13] 2013 Renal transplant recipients 41.6 ± 11.3 58.2 ± 10.1 235/104 Multiple oral dose of CsA adjusted according to blood concentration CC (40) CT (163) TT (136) Wei [14] 2010 Bone marrow transplant recipients 21 ± 18 47.5 ± 23.7 54/54 Multiple oral dose of CsA adjusted according to blood concentration CC (11) CT (47) TT (50) Qiu et al [7] 2011 Bone marrow transplant recipients 21.7 ± 17. (12) CT (41) TT (38) Zhang [15] 2012 Bone marrow transplant recipients 35 ± 9 6 3 ± 10 24/16 Multiple oral dose of CsA adjusted according to blood concentration C (22) TT (18) Zhang [16] 2008 Myasthenia gravis recipients 40. Chen et al. Medicine (2017) 96:47 www.md-journal.com C 0 , C 2 . [19] This explains the reason why AUC is rarely reported in the included studies.
Trough concentration (C 0 ) and dose adjusted C 0 are the most common parameters in included studies. It is interesting to find there was no significant difference in C 0 . But a significant difference was showed in dose adjusted C 0 in included studies. This suggested that we could choose dose adjusted C 0 of pharmacokinetic parameters as a detection indicator, to further guide the rational use of cyclosporine dose in different genotype of MDR1 C1236T patients. Through subgroup analysis of dose adjusted C 0 , the results suggested there was difference between subjects carrying CC genotypes and TT genotypes.
Whole-blood levels at 2 hours after drug intake (C 2 ) seem to provide a good surrogate of AUC for dose adjustment, which may better reflect intestinal absorption because it decreases the role of hepatic metabolism and renal excretion. [20] Through subgroup analysis of adjusted C 2 , the results suggested there was significant difference between subjects carrying CC genotypes and CT genotypes, as well as CC genotypes and TT genotypes. However, this meta-analysis shows SNP C1236T has no significant difference in C max and daily dose, which might demonstrate that the effect of different C1236T genotypes on the availability of cyclosporine was limited.
Although this meta-analysis analyzed the correlation between pharmacokinetic parameters and genotypes of MDR1 C1236T, we recognized that our study still has limitations. First, since these studies are different in design, subjects, dosage, parameters, measurement method, and so on, selection bias exists in this meta-analysis. Second, C1236T is one of the MDR1 SNPs, meaning that it is not the only polymorphism that could influence the MDR1 expression. Third, this meta-analysis did not find a definitive correlation between pharmacokinetic parameters and genotype of MDR1 C1236T. Balram et al indicated race maybe one important factor affecting the pharmacokinetic parameters of cyclosporine. [21] Chowbay et al suggested that MDR1 haplotype, rather than single SNP polymorphism, might be responsible for influencing P-glycoprotein expression, thus influencing the pharmacokinetic parameters of cyclosporine. [22] Cyclosporine is also the substrate of CYP3A4 and CYP3A5 and polymorphism of CYP3A has the potential to affect cyclosporine metabolism. [23] Therefore, many facts would affect the correlation between pharmacokinetic parameters and genotypes of MDR1 C1236T. It is hard to find a definitive correlation and we should be cautious with our results.
In summary, this meta-analysis demonstrated that MDR1 C1236T polymorphism may have a minor effect on cyclosporine pharmacokinetics in transplantation patients.
